| John Moran |
John Moran is currently the Chief Operating Officer at Arhaus, Inc. He previously held the same position at Canada Goose Holdings, Inc. from 2014 to 2024. |
| Nicole Rusaw-George |
Nicole Rusaw-George is currently the Chief Financial Officer at Liminal BioSciences, Inc. She has previously worked as the Chief Financial Officer, Director & Secretary at Klinik Health Ventures Corp., Chief Financial Officer at Nuvo Pharmaceuticals, Inc., Vice President-Finance at Transition Therapeutics, Inc., and Chief Financial Officer at Copland Road Capital Corp. She also briefly served as the Chief Financial Officer at Ionic Brands Corp. Ms. Rusaw-George obtained an undergraduate degree from Brock University. |
| Patrick Sartore |
Patrick Sartore is currently the Director at Liminal BioSciences Ltd., Secretary & Director at ProMetic Pharma SMT Holdings Ltd., and Director at Fairhaven Pharmaceuticals, Inc. He previously held positions as President at Liminal BioSciences, Inc., Member of the Québec Bar Association, Member of the Intellectual Property Institute of Canada, and Member of the Association du Jeune Barreau de Montréal. Before his current roles, he was Chairman of ProMetic Plasma Resources, Inc., Secretary & Director of Astrea Bioseparations Ltd., Associate Attorney at Léger Robic Richard LLP, and Legal Counsel at Univalor, Inc. Mr. Sartore obtained his undergraduate degree from Concordia University and his graduate degree from the University of Montréal in 1999. |
| Bruce Philip Pritchard |
Bruce Philip Pritchard is currently the Chief Executive Officer at Liminal BioSciences, Inc. since 2020. He also holds the position of Non-Executive Director at Being Digital Ltd., Porton Biopharma Ltd., Fairhaven Pharmaceuticals, Inc., and Scottish Global Health Foundation. In his former roles, Mr. Pritchard served as the Chief Executive Officer & Director at ProMetic Plasma Resources, Inc. He was also a Senior Director at CV Therapeutics, Inc. from 2004 to 2006 and Finance Director at Ardana Plc from 2003 to 2004. Additionally, he held positions as a Director at Astrea Bioseparations Ltd., Non-Executive Director at Imanova Ltd. from 2012 to 2017, Director at Liminal BioSciences Ltd., and Chief Financial Officer at ProMetic BioSciences Ltd. Mr. Pritchard is a Member of The Institute of Chartered Accountants of Scotland from 2009 to 2015. He was also a Member-Examiners Board at The Institute of Directors (United Kingdom) from 2011 to 2016. Mr. Pritchard obtained his undergraduate degree from Heriot-Watt University in 1993. |
| Alek Krstajic |
Alek Krstajic is the founder of Public Mobile Holdings, Inc. He is currently the Non-Executive Chairman at Liminal BioSciences, Inc. His former positions include Chief Executive Officer at Public Mobile, Inc. and Freedom Mobile, Inc., Director at ViXS Systems, Inc., Executive Vice President & President-Wind at Shaw Communications, Inc., Vice President-Marketing at The Bell Telephone Company of Canada, Senior Vice President-Sales & Marketing at Rogers Cable, Inc., Senior Vice President at Rogers Communications, Inc., and Advisor at Summerhill Venture Partners, Inc. He obtained an undergraduate degree from the University of Toronto. |
| Simon Geoffrey Best |
Simon Geoffrey Best founded Par Fund Management Ltd. in 2008, Ardana Plc in 2000, where he worked as Non-Executive Chairman from 2010 to 2011, Biotechnology Innovation Organization in 1994, where he worked as Chief Executive Officer & Director from 1994 to 2005, and various other companies. Mr. Best also founded The Bioindustry Association, where he worked as Chairman & Chief Executive Officer and Simplex Services, Inc., where he is working as Chief Executive Officer. Mr. Best also currently works at Liminal BioSciences, Inc., as Lead Independent Director from 2019, Doyle Foundation, as Director, Evofem Biosciences Operations, Inc., as Director, and various other companies. Mr. Best also formerly worked at Geron Bio-Med Ltd., as Chief Executive Officer, Aquapharm Biodiscovery Ltd., as Chief Executive Officer from 2010 to 2012, Zeneca Plant Science, as Chief Executive Officer & Managing Director, and various other companies. Mr. Best received his undergraduate degree from The University of York and Masters Business Admin degree from London Business School. |
| Gary J. Bridger |
Gary J. Bridger founded AnorMED, Inc. in 1996, where he worked as Chief Scientific Officer, VP-R&D from 2000 to 2016. Dr. Bridger also currently works at Liminal BioSciences, Inc., as Director & Chief Scientific Officer from 2022, Expansion Therapeutics, Inc., as Director from 2022, X4 Pharmaceuticals, Inc., as Director, and Five Corners Capital, Inc., as General Partner from 2013. Dr. Bridger also formerly worked at Arsanis, Inc., as Director, X4 Pharmaceuticals, Inc., as Director, Celator Pharmaceuticals Corp., as Director, Lundbeck Seattle BioPharmaceuticals, Inc., as Independent Director from 2013 to 2016, Aquinox Pharmaceuticals, Inc., as Independent Director from 2013 to 2019, NeurAxon, Inc., as Director, Presidio Advisors, Inc., as Director, Genzyme Corp., as Senior Vice President-Research & Development from 2006 to 2007, Xenon Pharmaceuticals, Inc., as Executive Vice President-Research & Development from 2013 to 2015, and Ventures West Management, Inc., as Venture Partner from 2010 to 2012. Dr. Bridger received his doctorate degree in 1987 from the University of Manchester Institute of Science & Technology. |
| Neil A. Klompas |
Neil A. Klompas is an Independent Director at Liminal BioSciences, Inc., a Director at Ovensa, Inc., a Director at Canadian Gene Cure Foundation, and a Member at The Chartered Professional Accountants of British Columbia. He was previously the Chief Operating Officer at Zymeworks BC, Inc. and Zymeworks, Inc., a Manager-Mergers & Acquisitions Transactions at KPMG LLP, and an Audit Manager at KPMG LLP (Canada). He received an undergraduate degree from the University of British Columbia. |
| Timothy Steven Wach |
Timothy Steven Wach is currently an Independent Director at Liminal BioSciences, Inc. since 2019 and a Director at Alvarez & Marsal Taxand UK LLP since 2015. Previously, he served as a Managing Director & Director at Taxand Economic Interest Grouping from 2015 to 2020. He also worked as the Chief Legislative Counsel for the Government of Canada from 2009 to 2011. Prior to that, he was a Partner at Gowling Lafleur Henderson LLP from 1992 to 2014. |
